Eli Lilly Gets Buy Upgrade as Foundayo Demand Accelerates

Eli Lilly just got another vote of confidence from Wall Street — and this one comes with real numbers behind it.

Berenberg upgraded LLY to Buy from Hold on Tuesday and lifted its price target to $1,400 from $1,220, implying roughly 25% upside from current levels. Shares rose about 1.6% in premarket trading on the news, pushing above $1,155.

The upgrade isn't just an analyst chasing momentum. Berenberg's Kerry Holford argues Lilly could beat its own already-ambitious 2026 revenue guidance of $85 billion to $87 billion, driven by accelerating demand for its obesity and diabetes drugs.

The star of that thesis is Foundayo, Lilly's once-daily oral GLP-1 treatment that won FDA approval in April and doesn't require food or water restrictions to take. Early uptake has been fast: Lilly says Foundayo has already captured more than 30% of new U.S. patients starting oral weight-loss medications.

That's a meaningful number for a drug that's barely five months old on the market. It suggests doctors and patients are choosing the pill over the needle at a faster clip than many analysts had modeled, and it gives Lilly a growth lever that doesn't depend solely on scaling up injectable manufacturing capacity.

"Analyst Kerry Holford raised her price target to $1,400 from $1,220, implying nearly 25% upside and reinforcing Lilly's status as Wall Street's dominant obesity-drug bet."

That matters for investors because oral drugs solve two problems at once. They attract patients who don't want injections, widening the addressable market, and they ease manufacturing bottlenecks that have constrained injectable treatments like Zepbound and Mounjaro. A bigger, easier-to-serve market is exactly what turns a good drug into a great stock.

Berenberg isn't alone in liking what it sees. Citigroup reiterated its own Buy rating on Lilly this week with a Street-high $1,600 price target, pointing to the same Foundayo momentum. Two independent research desks landing on bullish calls within days of each other, both centered on the same catalyst, is the kind of confirmation that's hard to dismiss as noise.

For investors, the appeal of LLY right now isn't just the obesity-drug franchise everyone already knows about — it's what the company does with the cash that franchise generates. Berenberg specifically flagged Lilly's reinvestment into its broader pipeline, including next-generation obesity candidate retatrutide, as a reason the stock deserves a higher multiple than a single-drug story would command.

Retatrutide, if it eventually reaches the market, targets even greater weight loss than current GLP-1 drugs by working on three separate hormone receptors instead of one or two. It's still in late-stage trials, but it's the kind of pipeline depth that keeps Lilly's growth story from being a one-drug bet years down the road.

There's a risk worth weighing before chasing the stock at current levels. Lilly trades at a premium valuation built almost entirely on continued execution in obesity and diabetes — any stumble in Foundayo adoption, a competitive setback against rivals like Novo Nordisk, or slower-than-expected uptake could hit the stock hard given how much optimism is already priced in.

Novo Nordisk isn't standing still either. Its own oral GLP-1 candidates are working through the pipeline, and any signal that Novo is closing the gap on convenience or pricing would be the first thing to watch for cracks in Lilly's current lead.

What to watch next: Lilly's next quarterly update should show whether Foundayo's 30%-plus share of new oral GLP-1 starts is holding or growing, since that number is the crux of the bull case. Also keep an eye on any pricing or reimbursement news out of Washington, since obesity-drug affordability remains a political flashpoint heading into the midterms.

For investors already holding LLY, the twin upgrades from Berenberg and Citigroup support staying the course rather than trimming into strength. For those looking to start a position, a pullback toward the $1,100 area — if the broader market gives one on rate jitters — would offer a more comfortable entry than chasing shares at the highs.

Bottom line: Lilly's obesity pipeline keeps clearing hurdles analysts thought would take years to clear, and Wall Street is racing to raise targets rather than waiting for the next earnings report to confirm it.